Biomarkers for Lung Cancer Testing
March 21, 2014
Optimal Lung Cancer Treatment Requires Biomarker Testing
Biomarkers for lung cancer testing and biomarker testing are the subject of this important medical segment. Join Drs Gary Palmer and Deborah Morosini of Foundation Medicine as they share insight on the importance of testing and multidisciplinary coordination in its implementation and success. You’ll learn how this has had personal impact, and how the diagnosis and treatment of lung cancer is rapidly evolving. Learn how physicians are prolonging and improving the lives of cancer victims. Visit www.LetsTestNow.com or www.BoehringerIngelheim.com
Behind the Mystery is a special segment dedicated to revolutionizing the way the health care system works for those suffering from a rare and genetic disorder.
Behind the Mystery takes a closer look at one of the two types of Polycystic Kidney disease. Autosomal Dominant Polycystic Kidney Disease, or ADPKD, is a rare, genetic condition.
Behind the Mystery takes a closer look at Blastic Plasmacytoid Dendritic Cell Neoplasm, a rare disease that is often misdiagnosed and affects at least 500 to 1,000 patients each year in the U.S.